Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Progress in Neuro-psychopharmacology and Biological Psychiatry

• Publication date

  2010-02-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.pnpbp.2009.09.023PMID 19793544
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population.

  2010cited by this paper
• Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone

  2009cited by this paper
• Management of non-motor symptoms in advanced Parkinson disease.

  2008cited by this paper
• Use of antihypertensives and the risk of Parkinson disease

  2008cited by this paper
• The sensitivity and specificity of the 9-item Wearing-off Questionnaire.

  2008cited by this paper
• Striatal dopaminergic activity (FDOPA‐PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease

  2007cited by this paper
• Efficacy of Treatment for Somatoform Disorders: A Review of Randomized Controlled Trials

  2007cited by this paper
• Prevalence and treatment of non-motor symptoms in Parkinson's disease.

  2007cited by this paper
• Somatoform disorders and recent diagnostic controversies.

  2007cited by this paper
• Neurophysiologic study of central pain in patients with Parkinson disease

  2007cited by this paper
• Explaining medically unexplained symptoms-models and mechanisms.

  2007cited by this paper
• Non-motor dysfunction in Parkinson's disease.

  2007cited by this paper
• The association of depression and anxiety with medical symptom burden in patients with chronic medical illness.

  2007cited by this paper
• Pramipexole: Augmentation in the Treatment of Depressive Symptoms

  2006cited by this paper
• Symptoms, syndromes, and the value of psychiatric diagnostics in patients who have functional somatic disorders.

  2006cited by this paper
• End-of-dose Wearing Off in Parkinson Disease: A 9-Question Survey Assessment

  2006cited by this paper
• The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors?

  2006cited by this paper
• Physical symptoms as a predictor of health care use and mortality among older adults.

  2005cited by this paper
• Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment

  2005cited by this paper
• Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.

  2005cited by this paper
• Levodopa Challenge Neuroimaging of Levodopa-Related Mood Fluctuations in Parkinson's Disease

  2005cited by this paper
• Prevalence and treatment of depression in Parkinson's disease.

  2005cited by this paper
• The non-motor symptom complex of Parkinson’s disease: A comprehensive assessment is essential

  2005cited by this paper
• Effect of levodopa on pain threshold in Parkinson's disease: A clinical and positron emission tomography study

  2005cited by this paper
• A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.

  2005cited by this paper
• Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation.

  2003cited by this paper
• Prevention and treatment of motor fluctuations.

  2003cited by this paper
• The PHQ-15: Validity of a New Measure for Evaluating the Severity of Somatic Symptoms

  2002cited by this paper
• Dopamine D2 receptor binding in the human brain is associated with the response to painful stimulation and pain modulatory capacity

  2002cited by this paper
• Placebo in clinical trials for depression: complexity and necessity.

  2002cited by this paper
• Relevance of motor complications in Parkinson’s disease

  2002cited by this paper
• Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling

  2002cited by this paper
• Non-recognition of depression and other non-motor symptoms in Parkinson's disease.

  2002cited by this paper
• The Clinical Profile of Nonmotor Fluctuations in Parkinson's Disease Patients

  2002cited by this paper
• Factors impacting on quality of life in Parkinson's disease: Results from an international survey

  2002cited by this paper
• Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease.

  2001cited by this paper
• Prospective longitudinal assessment of hallucinations in Parkinson’s disease

  2001cited by this paper
• Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

  2000cited by this paper
• DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee.

  1999cited by this paper
• Motor fluctuations in Parkinson's disease: pathophysiology and treatment

  1999cited by this paper
• Nonmotor fluctuations in patients with Parkinson's disease

  1996cited by this paper
• The importance of placebo effects in pain treatment and research.

  1994cited by this paper
• What features improve the accuracy of clinical diagnosis in Parkinson's disease

  1992cited by this paper
• Parkinson's disease: pathophysiology

  1991cited by this paper
• Mood changes and “on‐off” phenomena in Parkinson's disease

  1990cited by this paper
• "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

  1976cited by this paper

• Impact of levodopa and deep brain stimulation on visual impairments in Parkinson’s disease

  2025cites this paper
• Gender Is the Main Predictor of Wearing‐Off and Dyskinesia in Levodopa‐Naïve Patients with Parkinson's Disease

  2025influential citation
• Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies

  2023cites this paper
• The role of genetics and gender specific differences in neurodegenerative disorders: Insights from molecular and immune landscape.

  2023cites this paper
• Both Motor and Non-Motor Fluctuations Matter in the Clinical Management of Patients with Parkinson’s Disease: An Exploratory Study

  2023cites this paper
• [Characteristics and treatment of pain in Parkinson's disease].

  2022cites this paper
• Pharmacological management of Parkinson’s disease motor symptoms: update and recommendations from an expert

  2022cites this paper
• Somatoform Symptoms in Parkinson Disease

  2022cites this paper
• The Efficacy of Tai Chi and Stretching Exercises Based on a Smartphone Application for Patients With Parkinson's Disease: A Protocol for a Randomized Controlled Trial

  2021cites this paper
• Diagnosis and Management of Pain in Parkinson's Disease: A New Approach

  2021cites this paper
• Response to "Comment on: "Point of view: Wearable systems for at-home monitoring of motor complications in Parkinson's disease should deliver clinically actionable information".

  2021cites this paper
• Could New Generations of Sensors Reshape the Management of Parkinson’s Disease?

  2021cites this paper
• Gender Differences and Quality of Life in Parkinson’s Disease

  2020cites this paper
• 123I-Ioflupane dopamine transporter imaging (DaTSCAN) appearances in relation to emotional responsiveness, impulsivity and olfaction in suspected Parkinsonian syndrome

  2020cites this paper
• Reversal of hyperactive subthalamic circuits differentially mitigates pain hypersensitivity phenotypes in parkinsonian mice

  2020cites this paper
• Shedding light on depressive, anxiety and sleep disorders in Parkinson's disease

  2019cites this paper
• Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines from Saudi Parkinson Patients

  2019cites this paper
• Palliative Care in Neurological Diseases

  2019cites this paper
• Odorants: a tool to provide nonpharmacological intervention to reduce anxiety during normal and pathological aging.

  2019cites this paper
• Erratum to “Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines from Saudi Parkinson Patients”

  2019cites this paper
• Serotonergic neurons mediate the anxiolytic effect of l-DOPA: Neuronal correlates in the amygdala.

  2018cites this paper
• LOWE 123 IFP-CIT BINDING TO THE STRIA AL DOPAMINE TRANSPORTER , BUT NOT TO TH EXTRASTRIATAL SEROTONIN TRANSPORTER , IN PARKINSON ’ S DISEASE COMPARED WITH DEMENTIA WITH LEWY BODIES 3

  2018cites this paper
• Clinimetrics of the 9- and 19-Item Wearing-Off Questionnaire: A Systematic Review

  2018cites this paper
• Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease

  2018cites this paper
• Understanding, Impact, and Communication of “Off” Periods in Parkinson's Disease: A Scoping Review

  2018cites this paper
• Prevalence and risk factors for depression and anxiety in Chinese patients with Parkinson disease

  2017cites this paper
• Psychosis in parkinsonism: an unorthodox approach

  2017cites this paper
• Somatization in Parkinson's Disease: A systematic review

  2017influential citation
• Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics.

  2017cites this paper
• Altered putamen functional connectivity is associated with anxiety disorder in Parkinson's disease

  2017cites this paper
• Serotonin transporter binding and anxiety symptoms in Parkinson’s disease

  2017cites this paper
• The Non-motor Parkinson’s Disease

  2017cites this paper
• Predictors of anxiety in early-stage Parkinson's disease - Results from the first two years of a prospective cohort study.

  2017cites this paper
• Dopaminergic drugs decrease loss aversion in Parkinson’s disease with but not without depression

  2016cites this paper
• Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines.

  2016cites this paper
• The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations

  2016cites this paper
• Parkinsonism and Related Disorders

  2016cites this paper
• Optimal Treatment in Parkinson’s Disease: Pharmacotherapy and Practical Tips

  2015cites this paper
• Utility of the Japanese version of the 9-item Wearing-off Questionnaire.

  2015cites this paper
• The “Gender Factor” in Wearing-Off among Patients with Parkinson's Disease: A Post Hoc Analysis of DEEP Study

  2015cites this paper
• Unraveling predictors affecting compliance to MRI in Parkinson's disease.

  2015cites this paper
• Virtually-induced threat in Parkinson's: Dopaminergic interactions between anxiety and sensory-perceptual processing while walking.

  2015cites this paper
• A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer—VBM study

  2015cites this paper
• Surgical Options for Levodopa-Induced Dyskinesia in Parkinson’s Disease

  2014cites this paper
• Motor Impairment and Disability Scales

  2014cites this paper
• Les systèmes monoaminergiques : implication dans la physiopathologie et la thérapie de la maladie de Parkinson

  2014cites this paper
• Clinical features and varieties of non-motor fluctuations in Parkinson's disease: a Japanese multicenter study.

  2013cites this paper
• Rotigotine for anxiety during wearing-off in Parkinson’s disease with dementia

  2013influential citation
• Physical Symptoms in Neurological Conditions

  2013cites this paper
• Levodopa treatment and mood fluctuation in dementia with Lewy bodies: a case report

  2013cites this paper
• Behavioral characterization of the 6-hydroxidopamine model of Parkinson’s disease and pharmacological rescuing of non-motor deficits

  2013cites this paper
• Neurological diseases and pain.

  2012cites this paper
• Differential effects of dopaminergic medication on basic motor performance and executive functions in Parkinson's disease.

  2012cites this paper
• A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.

  2012cites this paper
• Complexity of Motor Response to Different Doses of Duodenal Levodopa Infusion in Parkinson Disease

  2012cites this paper
• Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease?

  2012cites this paper
• Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.

  2012cites this paper
• Pain Perception, Pain Drug Therapy and Health Status in Patients with Parkinson’s Disease

  2011cites this paper
• Role of L-DOPA in spinal nociceptive reflex activity: higher sensitivity of Aδ versus C fibre-evoked nociceptive reflexes to L-DOPA.

  2011cites this paper
• Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

  2011cites this paper
• Pharmacological therapy of Parkinson's disease: current options and new avenues.

  2010cites this paper
• Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.

  2010cites this paper
• Author ' s personal copy

  year unknowncites this paper